On the BBC today talking about British patient access to emerging technologies and the challenges health-tech companies face in the widespread adoption of their technologies in the UK.
Last week, we were proud to present two abstracts at the San Antonio Breast Cancer Symposium 2024. The first abstract showcased head-to-head data from Charing
We’re excited to announce that Digistain® has partnered Deloitte to drive adoption across Europe! This collaboration marks a significant step toward making breast cancer risk
We’re thrilled to announce that Digistain® is now available to over 60% of UK private patients, with reimbursement available though Bupa, WPA Health Insurance &
Supported by:
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.